Siwa was founded in 2005 to develop tyrosylprotein sulfotransferase (TPST) inhibitors to be used as a male contraceptive with anti-HIV activity. TPST’s post-translationally sulfate tyrosine residues in proteins. In 2012, this project was terminated due to technical challenges.
Our interest in blood typing reagents began because of a report that DARC (Duffy Antigen Receptor for Chemokines) carried a tyrosine sulfate residue immediately adjacent to the polymorphic amino acid that specifies the Duffy blood types Fya and Fyb. Armed with the knowledge that the minimal Duffy antigens may include tyrosine sulfate, we developed a strategy to generate monoclonal antibodies to Fya and Fyb using antigens containing tyrosine sulfate.
To accomplish this, we combined the knowledge accumulated at Siwa and our specific technical knowledge, and advances in immunology, molecular biology, and state- of-the-art monoclonal antibody production. We believe this approach to the rare blood typing reagent space where the average reagent is over twenty years old will be very productive.
Lea has more than 25 years of experience in the manufacture of monoclonal blood bank reagents as manager of Raw Material Manufacturing at Immucor and manager of Monoclonal Reagents at Gamma Biologicals.
Carolyn has more than 30 years of experience in immunohematology, which includes serving as vice president, worldwide field quality and technical support at Immucor, director of education and IRL at the American Red Cross, and technical director of transfusion services and donor testing labs at a Community Blood Center
Mike has spent more than 35 years in the blood bank diagnostic Industry, beginning his career in sales with Ortho Diagnostics and then becoming involved in the startup of two blood bank companies, BCA and Immucor. He served a combined 25 years as director, then vice president of sales at Immucor.
Hailey has several years experience in the healthcare industry, beginning her career as a pharmaceutical sales representative and then joining Immucor as a blood bank automation specialist with sales responsibility for the southeastern US territory.
Carol has more than 30 years experience in immunohematology, serving as an assistant blood bank supervisor in a large trauma center and then as a supervisor of a large hospital transfusion service. She was a sales representative for both Gamma Biologicals and Immucor, as well as a regional manager at Immucor.
Frank has spent more than 30 years in the blood bank diagnostic industry, beginning his career with Ortho Diagnostics and then becoming involved in the start ups of BCA and Immucor.
In addition to the employees above, Siwa Biotech, is comprised of a very experienced and highly qualified group of MD, and PhD scientists dedicated to the development of new clones producing monoclonal blood typing reagents.
Siwa was founded in 2005 by Drs. William Canfield (Chairman and CEO) and Kevin Moore (President). Both are trained Hematologists/Oncologists and former faculty at the University of Oklahoma Health Sciences Center. Dr. Canfield left the University in 1998 to found Novazyme Pharmaceuticals; subsequently acquired by Genzyme in 2001. From 2005-2015 he was Chairman of Cytovance Biologics until it was acquired by Hepalink. From 1998 to 2013 Dr. Moore was an investigator at the Oklahoma Medical Research Foundation a private, non-profit research institute in Oklahoma City, where he performed his groundbreaking research on TPSTs.